ChemoCentryx shareholders approve $3.7B merger with Amgen
ChemoCentryx shareholders have overwhelmingly approved Amgen's (NASDAQ:AMGN) $3.7B acquisition of the company.
With the acquisition, Amgen (AMGN) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare diseasesÂ characterized by destruction and inflammation of small vessels.
NASDAQ said ChemoCentryx's anticipated last day of trading will be Oct. 19.